Working in partnership with Ranking member Wyden, the Finance Committee delivered on our commitment to bring transparency and accountability to the prescription drug supply chain through pharmacy benefit manager reforms. The bipartisan law will end perverse incentives for PBMs to steer patients toward higher cost drugs. and vertically integrate pharmacies. Our work to address anticompetitive consolidation is just beginning and I look forward to continuing these efforts with Ranking member Wyden and all members of this committee on a bipartisan basis. (03:09–03:17)
CLAIM
Asserts that new legislation will address incentives in the prescription drug supply chain.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
